
Sofwave Medical is an energy-based maker of non-invasive aesthetic medical devices for practitioners worldwide.
sofwave.comCrawled Nov 15, 2026
Introducing the liftHD body applicator, the next generation of non-invasive aesthetic technology for treating the body.
Sofwave offers a £20,000 credit for non-invasive skin lifting devices, requiring no needles or fat loss
Sofwave uses ultrasound to stimulate collagen production in aging skin.
The company highlights anti-aging foods as important for maintaining a fresh complexion.
The best way to reverse wrinkles is to never develop them in the first place, these are best treatments for deep wrinkles
Browse Sofwave clinical studies FDA pivotal trials, brochures and white papers covering safety efficacy and results from peer reviewed ultrasound research.
Sofwave shares updates on FDA approvals, clinical achievements, and company growth.
Sofwave announces the debut of its liftHD Body Contouring Applicator at the 44th ASLMS meeting.
Sofwave’s SUPERB Non-Invasive Skin Treatment Technology received regulatory clearance in Japan.
Sofwave seeks an Area Sales Manager to drive sales of its aesthetic devices.
Sofwave provides career opportunities in the aesthetics industry.
Sofwave offers a Medical Clinical Educator role to support its aesthetic device innovations.
Shape the future of aesthetics as a Practice Development Manager at Sofwave. Lead practice success and be part of a groundbreaking team.
Sofwave offers a $25,000 credit for non-invasive skin lifting devices, requiring no needles or fat loss.
Sofwave promotes its Total Body Solution for aesthetic body contouring.
Filing Date Form Type Description Action 2025-03-13 SCHEDULE 13D/A [Amend] General Statement of Acquisition of Beneficial OwnershipAcc-no: 0001178913-25-000832 (34 Act) Size: 5 KB 2025-02-06 6-K/A [Amend] Report of foreign issuer [Rules 13a-16 and 15d-16]Acc-no: 0001178913-25-000344 (34 Act) Size: 673 KB 2025-02-04 S-8 Securities to be offered to employees in employee benefit plansAcc-no: 0001178913-25-000316 (33 Act) […]
Sofwave provides an Investor Relations page for stakeholders interested in the company.
Sofwave lists patents for its proprietary medical aesthetic treatment technologies.
SUPERB non-invasive technology for efficient growth of natural collagen, elastin, and hyaluronic acid, that lifts, tones, and improves skin laxity.
Sofwave Medical releases its third-quarter 2026 financial performance and key business updates. The company provides a snapshot of operational progress and financial metrics for investors and stakeholders. Details include revenue trends, product adoption, and strategic initiatives in its medical technology sector.
Sofwave Medical completes its one-millionth treatment globally, with the milestone procedure conducted in South Korea. The company specializes in minimally invasive therapies for musculoskeletal conditions. This achievement reflects growing adoption of its ultrasound-guided treatment solutions across international markets.
Sofwave Medical releases its second-quarter and first-half 2026 financial performance, detailing revenue growth and operational updates. The company highlights progress in its medical device pipeline, including advancements in ultrasound-based therapies. Sofwave continues to expand its commercial footprint while maintaining strong cash reserves.
Sofwave Medical releases its first-quarter fiscal 2026 financial results, detailing revenue growth and operational updates. The company highlights progress in its medical device pipeline, including advancements in ultrasound-based therapies. Sofwave continues to expand its commercial footprint, with key focus areas in cardiovascular and oncology applications.
Sofwave Medical reports its fourth-quarter and full-year 2025 financial results, marking the company’s first year of profitability. The medical technology firm highlights operational milestones and revenue growth in its core ultrasound-based treatment platforms. Sofwave’s financial update follows a period of expanding commercial adoption and strategic investments in R&D.
Sofwave Medical releases its **2024 financial results**, detailing performance for the fourth quarter and full year. The company highlights key operational and business developments, though specific metrics or milestones are not disclosed in the brief announcement. Sofwave Medical continues to focus on its medical technology innovations, targeting advancements in surgical or procedural solutions.